NCT00600353 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 18
- units
- Participants
- groups
- description
- Group A: Subjects with Multiple Myeloma * Conditioning regimen, over a 7 day period, includes: * Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion Group B: Subjects with Lymphoma * Conditioning regimen, over a 7 day period, includes: (BEAC) * BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant
- id
- BG000
- title
- Subjects With Multiple Myeloma
- description
- Includes patients with Hodgkin's Disease and Non-Hodgkin's lymphoma
- id
- BG001
- title
- Group B Lymphoma
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 11
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 18
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 0
- upper Limit
- 9
- value
- 9
- group Id
- BG001
- lower Limit
- 0
- upper Limit
- 9
- value
- 9
- group Id
- BG002
- lower Limit
- 0
- upper Limit
- 18
- value
- 9
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- emetic response, adverse events, quality of care
- unit Of Measure
- participants
- population Description
- 2 patients excluded from analysis
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 18
- units
- Participants
- groups
- description
- Group A: Subjects with Multiple Myeloma * Conditioning regimen, over a 7 day period, includes: * Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion Group B: Subjects with Lymphoma * Conditioning regimen, over a 7 day period, includes: (BEAC) * BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant
- id
- BG000
- title
- Subjects With Multiple Myeloma
- description
- Includes patients with Hodgkin's Disease and Non-Hodgkin's lymphoma
- id
- BG001
- title
- Group B Lymphoma
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 11
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 18
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 0
- upper Limit
- 9
- value
- 9
- group Id
- BG001
- lower Limit
- 0
- upper Limit
- 9
- value
- 9
- group Id
- BG002
- lower Limit
- 0
- upper Limit
- 18
- value
- 9
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- emetic response, adverse events, quality of care
- unit Of Measure
- participants
- population Description
- 2 patients excluded from analysis
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle